Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma

Inclusion Criteria:

- Men or women ≥ 60 years old with estimated life expectancy of ≥ 5 years

- Histopathologic diagnosis of basal or squamous cell carcinoma

- Clinical stage T1N0M0 (by AJCC 2010 criteria)

°Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or
micronodular features must be ≤1 cm

- Low risk pathologic features (by AJCC 2010 criteria)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (Appendix C)

- Able and willing to complete the Skindex16 and Skin Cancer Index (must be able to
speak English)

- Ability to provide informed consent

Exclusion Criteria:

- BCC/SCC that was previously treated (ie, recurrent BCC/SCC)

- BCC/SCC in region adjacent to or overlapping with region of prior radiotherapy

- BCC/SCC on irregular surface (ie, target area not flat)

- BCC/SCC adjacent to or overlapping with burn or scar

- BCC/SCC in area prone to trauma (including, but not limited to the skin overlying the
tibia, dorsum of hands and elbow)

- BCC/SCC in area with compromised lymphatic drainage or vascular supply

- BCC/SCC within 3 cm of another treated or untreated BCC/SCC

- Inflammatory process in target area

- Collagen vascular disease (lupus, scleroderma, rheumatoid arthritis)

- Diabetes that is poorly controlled

- Genetic disorder predisposing patient to skin cancers or radiation sensitivity (basal
cell nevus syndrome, xeroderma pigmentosum, ataxia telangiectasia mutans)

- Receipt of treatment with another investigational device or drug

- Receipt of drug that will affect biologic response to radiation (radiosensitizer or
radioprotector)

- High likelihood of protocol non-compliance (in opinion of investigator)